Related Experiment Video
Updated: Oct 26, 2026

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease
Published on: April 28, 2019
Clinical Progression, Viral Load Dynamics, and Immune Kinetics of Nipah Virus Infection: Nipah Virus Kinetics Study
Anika Farzin1, Shadman Sakib Choudhury1, Wasik Rahman Aquib1
1International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Background:
Nipah virus (NiV) is a zoonotic pathogen with pandemic potential. Understanding the immune response to this pathogen is important for developing vaccines and therapeutics. This study aims to characterize viral load, host immune kinetics, and biomarker progression throughout NiV infection.
Methods:
We will utilize the ongoing NiV surveillance platform in Bangladesh to enroll individuals with confirmed NiV infection. Oropharyngeal swabs and blood samples will be collected following the protocol. Oropharyngeal swabs will be taken daily until two consecutive negative results are obtained. Blood samples will be collected every 48 hours from initial detection of the virus until discharge from the hospital to assess IgM and IgG. Among survivors, 5 ml of blood will be collected every 15 days for 3 months from initial detection of the virus and then every 30 days up to 6 months. Viral load will be measured using RT-qPCR. Immune kinetics will be assessed using quantitative enzyme-linked immunosorbent assay (ELISA), and biomarkers will be analyzed via ELISA. Clinical progression, viral load, immune response, and biomarker patterns will be observed and documented.
Discussion:
The study is expected to characterize the temporal trends of viral load and immune responses and examine their association with clinical progression, epidemiological indices, and disease outcome. Findings from this study could enhance understanding of the human immune response to NiV and inform diagnostic schedules and vaccine and therapeutics development. © 2026 The Author(s). Current Protocols published by Wiley Periodicals LLC.

